Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | 4 Parkinson's trials, 1 stopped | 0.80 |
| literature PubMed | 12 Parkinson's papers of 153 | 0.66 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 4617
Sealed predictions
- NRGN in dopamine neurons, braak+0.05 (p 0.892) → -0.02 (p 0.964)receipt 4626
Swarm cases
receipt 4626: NRGN in dopamine neurons, braak
- power
- full sample -0.01 (p 0.956, n 18), 95% CI -0.48 to +0.46. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.01 (p 0.962, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.21 (p 0.408, n 18). could be the mix.
- skeptic
- leave-one-out range -0.11 to +0.11, sign flips 7; without severely affected donors -0.01 (p 0.956, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NRGN in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts